Panteli Theocharous

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +5

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells

Elin Borgen, Bjørn Naume, Jahn M. Nesland et al. · Cytotherapy · 1999 · 265 citations

Immunostained Cells, Immunocytochemical Technique, Oncology +13

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong et al. · The Lancet Oncology · 2011 · 108 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab Versus Rituximab +6

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant

Rachel Pawson, Mike Potter, Panteli Theocharous et al. · British Journal of Haematology · 2001 · 73 citations

Baculovirus‐mediated expression and characterisation of rat glycogen synthase kinase‐3β, the mammalian homologue of the <i>Drosophila melanogaster zeste‐white 3^sgg</i>, homeotic gene product

Kenneth Hughes, Bernd Pulverer, Panteli Theocharous et al. · European Journal of Biochemistry · 1992 · 56 citations · Full text